Coreline Soft CFO’s Share Purchase Signals Confidence in Global Medical AI Expansion

Market attention is focused on management’s confidence ahead of an expansion in the global medical AI market after Coreline Soft Executive Director and CFO Woo-seok Jung was reported to have purchased 845 shares of the company’s stock on the open market. According to the Data Analysis, Retrieval and Transfer System (DART), Jung bought a total of 845 common shares in 12 transactions from Aug. 18 through the 7th of this month at an average price of 2,526 won per share, increasing his holdings from 56,646 to 57,491 shares.

Global regulatory milestones coincide with CFO’s share purchases

The share purchases coincided with the company securing regulatory approvals in key overseas markets. Coreline Soft announced Sept. 14 that its AVIEW Lung Nodule computer-aided detection (CAD) solution for detecting lung nodules on chest CT scans had received approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). It is the first product developed in South Korea to receive approval in the CT-based computer-aided diagnosis field for lung nodules, and the fourth globally.

Following the approval, the company secured about 80 hospitals as customers in Japan. That figure represents a roughly twofold increase in its local customer base in just over a year. The extensive real-world data and operational expertise accumulated through South Korea’s national lung cancer screening program, which has been in place since 2019, are seen as assets in expanding into overseas markets.

National screening contracts in Germany, Australia and elsewhere shift revenue model

Progress is also becoming evident in Europe. Since April this year, low-dose CT lung cancer screening for high-risk groups has been covered under Germany’s statutory health insurance system. Coreline Soft is rapidly gaining ground, with 77 new customer contracts secured through July. In Australia, the company supplies its solution to the National Lung Cancer Screening Program (NLCSP), where it is currently being used in about 30,000 screenings, equivalent to about 40% of the country’s total national screening volume.

This overseas expansion is closely tied to a fundamental change in the business model. The company is moving beyond one-time software sales to a recurring revenue model that charges per screening (SaaS). In a report published Sept. 23, SK Securities said, "With screening infrastructure adoption following reimbursement in Germany and a foundation for expansion in Japan and North America, the increase in installations in 2026 will begin to be reflected in per-screening revenue in earnest in 2027."

Jin-mo Koo, a professor of radiology at Seoul National University Hospital, also said at a World Conference on Lung Cancer (WCLC) symposium on Sept. 11, "As national lung cancer screening expands, a system capable of efficiently handling the exponentially increasing volume of CT interpretations is essential." He added, "The role of medical AI must expand beyond the accuracy of lung nodule detection to encompass screening operations as a whole."

Turnaround expected in 2027, with potential to become a platform

The timing of management’s share purchases also coincides with expectations for improved profitability. If infrastructure established in major countries, including Germany, Japan and Australia, leads to actual screening activity starting in the second half of 2026, stable per-screening recurring revenue is expected to be reflected in the financial statements in earnest in 2027, increasing the likelihood that the company will move out of a loss-making structure.

Coreline Soft is seeking to evolve beyond AI that simply assists with image interpretation and become an integrated medical screening infrastructure platform that supports simultaneous analysis of multiple diseases, including lung cancer, chronic obstructive pulmonary disease and cardiovascular disease, as well as comparison with prior images and follow-up care. The time is approaching for the company to prove through its results whether the CFO’s share purchase reflects confidence in a business model transition rather than simply an effort to support the stock price.